Chinese alternative asset fund manager CDH Investments and Beijing-based Leadyond Capital have led a RMB250 million (US$39 million) series B round in Chengdu-based drug discovery firm HitGen, according to HitGen’s announcement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?